Table 1.
Distribution of clinical characteristics by ECOG PS
| Clinical characteristic | ECOG PS 0–1 | ECOG PS 2 |
| N=195 (%) | N=39 (%) | |
| Age, median (range) | 68 (35-92) | 73 (43-91) |
| Age | ||
| <70 | 111 (56.9) | 17 (43.6) |
| ≥70 | 84 (43.1) | 22 (56.4) |
| Sex | ||
| Male | 95 (48.8) | 20 (51.3) |
| Female | 100 (51.2) | 19 (48.7) |
| Smoking status | ||
| Current/former | 177 (90.8) | 37 (94.9) |
| Never | 18 (9.2) | 2 (5.1) |
| Histology | ||
| Adenocarcinoma | 150 (76.9) | 30 (76.9) |
| Squamous cell carcinoma | 25 (12.8) | 6 (15.4) |
| NSCLC NOS | 20 (10.3) | 3 (7.7) |
| Oncogenic driver mutation | ||
| KRAS | 65 (37.6) | 16 (45.7) |
| Potentially targetable oncogenes* | 26 (15.0) | 3 (8.6) |
| None identified | 82 (47.4) | 16 (45.7) |
| N.A. | 22 | 4 |
| Brain metastases | ||
| Absent | 146 (74.9) | 24 (61.5) |
| Present | 49 (25.1) | 15 (38.5) |
| PD-L1 expression | ||
| ≥90% | 99 (50.8) | 17 (43.6) |
| 50%–89% | 96 (49.2) | 22 (56.4) |
*Including (BRAF, MET, HER2, RET).
ECOG PS, Eastern Cooperative Oncology Performance Status; N.A., not available; NSCLC NOS, non–small cell lung cancer not otherwise specified; PD-L1, programmed cell death ligand 1.